1 – 7 of 7
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction : The phase 2a FLAVOUR study
(
- Contribution to journal › Article
- 2020
-
Mark
Design and rationale of FLAVOUR : A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction
(
- Contribution to journal › Article
- 2019
-
Mark
Treatments and Mortality Trends in Cases With and Without Dialysis Who Have an Acute Myocardial Infarction : An 18-Year Nationwide Experience
(
- Contribution to journal › Article
- 2017
-
Mark
Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease : A molecular and genetic association study
(
- Contribution to journal › Article
- 2016
-
Mark
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction
(
- Contribution to journal › Article
-
Mark
Outcome after percutaneous coronary intervention for different indications : Long-term results from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
(
- Contribution to journal › Article
- 2013
-
Mark
Population Trends in Percutaneous Coronary Intervention 20-Year Results From the SCAAR (Swedish Coronary Angiography and Angioplasty Registry)
(
- Contribution to journal › Article